In the last trading session, 1.73 million shares of the Immunome Inc (NASDAQ:IMNM) were traded, and its beta was 1.98. Most recently the company’s share price was $6.95, and it changed around -$1.2 or -14.72% from the last close, which brings the market valuation of the company to $604.31M. IMNM currently trades at a discount to its 52-week high of $26.70, offering almost -284.17% off that amount. The share price’s 52-week low was $8.12, which indicates that the current value has fallen by an impressive -16.83% since then. We note from Immunome Inc’s average daily trading volume that its 10-day average is 1.1 million shares, with the 3-month average coming to 949.56K.
Immunome Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended IMNM as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight.
Immunome Inc (NASDAQ:IMNM) trade information
Instantly IMNM has showed a red trend with a performance of -14.72% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 8.81 on recent trading dayincreased the stock’s daily price by 21.11%. The company’s shares are currently down -34.56% year-to-date, but still down -16.87% over the last five days. On the other hand, Immunome Inc (NASDAQ:IMNM) is -25.67% down in the 30-day period. We can see from the shorts that 9.3 million shares have been sold at a short interest cover period of 8.14 day(s).
The consensus price target as assigned by Wall Street analysts is $33, which translates to bulls needing to increase their stock price by 78.94% from its current value. Analyst projections state that IMNM is forecast to be at a low of $23 and a high of $35.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -38.15%. Immunome Inc earnings are expected to increase by 46.10% in 2025, but the outlook is positive 20.77% per year for the next five years.
IMNM Dividends
Immunome Inc’s next quarterly earnings report is expected to be released on 2025-Mar-18.
Immunome Inc (NASDAQ:IMNM)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 17.68% of Immunome Inc shares, and 57.67% of them are in the hands of institutional investors. The stock currently has a share float of 70.06%. Immunome Inc stock is held by 172.0 institutions, with REDMILE GROUP, LLC being the largest institutional investor. By 2024-06-30, it held 8.1579% of the shares, which is about 4.89 million shares worth $59.16 million.
FMR LLC, with 7.0257% or 4.21 million shares worth $50.95 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
T. Rowe Price Small-Cap Stock Fund, Inc. and T. Rowe Price Health Sciences Fund, Inc. were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.96 shares worth $13.6 million, making up 2.25% of all outstanding shares. On the other hand, T. Rowe Price Health Sciences Fund, Inc. held roughly 1.69 shares worth around $11.76 million, which represents about 1.95% of the total shares outstanding.
